Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Lo-Coco

Showing results (161-170 of 204) with videos related to

Pageof 21
Sort By:
Clinical Case Reports|December 17, 2016
All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with <i>NPM1</i>-mutated AML unfit for intensive chemotherapy and review of the literatureFabio Forghieri, Sara Bigliardi, Chiara Quadrelli, et al.
Oncotarget|April 22, 2017
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitroNélida I Noguera, Elvira Pelosi, Daniela F Angelini, et al.
British Journal of Haematology|July 15, 2011
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factorsRoberto Latagliata, Massimo Breccia, Paola Fazi, et al.
Blood|June 4, 2008
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemiaAlessandro M Vannucchi, Elisabetta Antonioli, Paola Guglielmelli, et al.
Cancer Medicine|May 27, 2021
Mutational profile of ZBTB16-RARA-positive acute myeloid leukemiaEmiliano Fabiani, Laura Cicconi, Anna Maria Nardozza, et al.
Blood|October 18, 2002
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-upGiuseppe Avvisati, Maria Concetta Petti, Francesco Lo-Coco, et al.
Haematologica|May 30, 2008
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemiaFrancesco Lo-Coco, Antonio Cuneo, Fabrizio Pane, et al.
Blood|May 24, 2018
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APLAnna Maria Testi, Andrea Pession, Daniela Diverio, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Leukemia Research|February 1, 2015
Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosisAngela Rago, Roberto Latagliata, Marco Montanaro, et al.
Pageof 21

Showing results (161-170 of 204) with videos related to

Sort By:
Pageof 21
Clinical Case Reports|December 17, 2016
All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with <i>NPM1</i>-mutated AML unfit for intensive chemotherapy and review of the literatureFabio Forghieri, Sara Bigliardi, Chiara Quadrelli, et al.
Oncotarget|April 22, 2017
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitroNélida I Noguera, Elvira Pelosi, Daniela F Angelini, et al.
British Journal of Haematology|July 15, 2011
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factorsRoberto Latagliata, Massimo Breccia, Paola Fazi, et al.
Blood|June 4, 2008
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemiaAlessandro M Vannucchi, Elisabetta Antonioli, Paola Guglielmelli, et al.
Cancer Medicine|May 27, 2021
Mutational profile of ZBTB16-RARA-positive acute myeloid leukemiaEmiliano Fabiani, Laura Cicconi, Anna Maria Nardozza, et al.
Blood|October 18, 2002
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-upGiuseppe Avvisati, Maria Concetta Petti, Francesco Lo-Coco, et al.
Haematologica|May 30, 2008
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemiaFrancesco Lo-Coco, Antonio Cuneo, Fabrizio Pane, et al.
Blood|May 24, 2018
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APLAnna Maria Testi, Andrea Pession, Daniela Diverio, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Leukemia Research|February 1, 2015
Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosisAngela Rago, Roberto Latagliata, Marco Montanaro, et al.
Pageof 21